Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Donald, Johns"'
Autor:
Klaus, Kucher, Donald, Johns, Frank, Wagner, Khalid, Abd-Elaziz, Caroline, Derne, Oleksandr, Sverdlov, Christian U, Pfister, Berthold, Langguth
Publikováno v:
Progress in brain research. 260
To evaluate efficacy and safety of BGG492 (selurampanel; an orally active, competitive AMPA glutamate receptor antagonist) in patients with moderate-to-catastrophic chronic subjective tinnitus. Study (NCT01302873) enrolled patients with subjective ti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::78132842ffd9edea75a6a469c9768ba7
https://pubmed.ncbi.nlm.nih.gov/33637230
https://pubmed.ncbi.nlm.nih.gov/33637230
Autor:
Klaus Kucher, Christian Pfister, Berthold Langguth, Khalid Abd-Elaziz, Donald Johns, Frank Wagner, Oleksandr Sverdlov, Caroline Derne
Publikováno v:
Progress in Brain Research ISBN: 9780128215869
To evaluate efficacy and safety of BGG492 (selurampanel; an orally active, competitive AMPA glutamate receptor antagonist) in patients with moderate-to-catastrophic chronic subjective tinnitus. Study (NCT01302873) enrolled patients with subjective ti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e5ed48cdb4450300aa71584e086f490
https://doi.org/10.1016/bs.pbr.2020.12.004
https://doi.org/10.1016/bs.pbr.2020.12.004
Autor:
Martin E. Schwab, Armin Curt, Klaus Kucher, Norbert Weidner, Steven Casha, Anis Mir, R Rupp, Rainer Abel, Renate Meindl, Donald Johns, Baltazar Gomez-Mancilla, Hagen Christopher Baron, Roland Thietje, Christian Pfister, Andreas Badke, Doris Maier
Publikováno v:
Neurorehabilitation and Neural Repair. 32:578-589
Background. Neutralization of central nervous system neurite growth inhibitory factors, for example, Nogo-A, is a promising approach to improving recovery following spinal cord injury (SCI). In animal SCI models, intrathecal delivery of anti-Nogo-A a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22d9da9c357f2e4b46200a29f8aa7078
https://doi.org/10.1177/1545968318776371
https://doi.org/10.1177/1545968318776371
Autor:
Toni Donchev, Baltazar Gomez-Mancilla, Gregor Hasler, Dan J. Stein, Maurizio Fava, Magdalena Ocwieja, Donald Johns, Daniel Rutrick, Brian Smith, Jang-Ho Cha, Ganesan Subramanian, Fabrizio Gasparini
Publikováno v:
Advances in Therapy. 34:524-541
To determine if mavoglurant (modified release) as an augmentation therapy to selective serotonin reuptake inhibitors (SSRIs) could have beneficial effects reducing Yale–Brown Obsessive Compulsive Scale (Y-BOCS) total score in patients with obsessiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12ffa5822cfb600f16cec98126a1e958
https://doi.org/10.1007/s12325-016-0468-5
https://doi.org/10.1007/s12325-016-0468-5
Autor:
Anne Tisserant, Ralph Paul Maguire, Alla Goloborodko, Erik Wallstroem, Anna Belova, Andrew M Wright, Eva Havrdova, Hideki Garren, Donald Johns
Publikováno v:
Journal of Neurology. 263:1287-1295
The objective of this study was to assess the effect of secukinumab, a monoclonal antibody that inhibits interleukin (IL)-17A, on number of new active brain magnetic resonance imaging (MRI) lesions in subjects with relapsing-remitting multiple sclero
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a171adf511f4807cfb48d18c5ef057e
https://doi.org/10.1007/s00415-016-8128-x
https://doi.org/10.1007/s00415-016-8128-x
A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia
Autor:
Baltazar Gomez-Mancilla, Jean-Christophe Corvol, Gurutz Linazasoro, Izabela Rozenberg, Karla Eggert, Alberto J. Espay, Daniela Berg, Christian Geny, Pascal Derkinderen, Judit Sovago, Johannes Schwarz, Fabrizio Stocchi, Franck Durif, Andrew Feigin, Dominik Feuerbach, Jean-Luc Houeto, Thérèse Di Paolo, Claudia Trenkwalder, Judith Jaeger, Andres O. Ceballos-Baumann, Lin Zhang, Paul Maruff, Markus Weiss, Christine Tranchant, Donald Johns, Alexander Storch, Emmanuel Broussolle, Annamaria Jakab, Hans Ulrich Hockey, Olivier Rascol, Jean-Philippe Azulay, Luc Defebvre, Michal Gostkowski
Publikováno v:
Movement Disorders. 31:1049-1054
Background This phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor α7 agonist AQW051 in patients with Parkinson's disease and levodopa-induced dyskinesia. Methods Pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c882682551fac6c67b7caa6c0d42915c
https://doi.org/10.1002/mds.26569
https://doi.org/10.1002/mds.26569
A randomized, placebo‐controlled trial of AFQ056 for the treatment of chorea in Huntington's disease
Autor:
Donald Johns, Josef Priller, Hugh Rickards, Anne Elizabeth Rosser, Ralf Reilmann, Nicole Pezous, Baltazar Gomez-Mancilla, Fabrizio Gasparini, Sigurd D. Süssmuth, Marie-Laure Rouzade-Dominguez, Ludger Schöls, Carsten Saft, Georg Bernhard Landwehrmeyer
Publikováno v:
Movement disorders 30(3), 427-431 (2015). doi:10.1002/mds.26174
Background This study investigated the hypothesis that AFQ056 (mavoglurant), a selective metabotropic glutamate receptor 5 antagonist, reduces chorea in Huntington's disease (HD). Methods This 32-day randomized, double-blind, parallel-group, proof-of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::602c69b139b1d22bb178cd5919fec1e1
https://doi.org/10.1002/mds.26174
https://doi.org/10.1002/mds.26174
Publikováno v:
British Journal of Clinical Pharmacology. 75:831-841
Aim Previous studies have shown transient decreases in heart rate (HR) following administration of sphingosine 1‐phosphate (S1P) receptor modulators including BAF312. This study was conducted to determine whether dose titration of BAF312 reduces or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e55c7e5c9448f8b232fa4f85bf1700b
https://doi.org/10.1111/j.1365-2125.2012.04400.x
https://doi.org/10.1111/j.1365-2125.2012.04400.x
Autor:
Baltazar Gomez-Mancilla, L. Fredrik Jarskog, Cristina Lopez-Lopez, Stephen R. Marder, M Deanna, Robert W. Buchanan, Dominik Feuerbach, Rhett Behrje, Li-Shiun Chen, Ralph Paul Maguire, Nicole Pezous, Donald Johns, Will J. Cronenwett, Michael P. Harms, Markus Weiss
Introduction AQW051, an α7-nicotinic acetylcholine receptor partial agonist, enhanced cognitive function in rodent models of learning and memory. This study evaluated brain activation during performance of a working memory task (WMT) and an episodic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c176e7befa02bcc13b9c306bf7e274b
https://escholarship.org/uc/item/7rk4869v
https://escholarship.org/uc/item/7rk4869v
A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia
Autor:
Claudia, Trenkwalder, Daniela, Berg, Olivier, Rascol, Karla, Eggert, Andres, Ceballos-Baumann, Jean-Christophe, Corvol, Alexander, Storch, Lin, Zhang, Jean-Philippe, Azulay, Emmanuel, Broussolle, Luc, Defebvre, Christian, Geny, Michal, Gostkowski, Fabrizio, Stocchi, Christine, Tranchant, Pascal, Derkinderen, Franck, Durif, Alberto J, Espay, Andrew, Feigin, Jean-Luc, Houeto, Johannes, Schwarz, Thérèse, Di Paolo, Dominik, Feuerbach, Hans-Ulrich, Hockey, Judith, Jaeger, Annamaria, Jakab, Donald, Johns, Gurutz, Linazasoro, Paul, Maruff, Izabela, Rozenberg, Judit, Sovago, Markus, Weiss, Baltazar, Gomez-Mancilla
Publikováno v:
Movement disorders 31(7), 1049-1054 (2016). doi:10.1002/mds.26569
This phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor α7 agonist AQW051 in patients with Parkinson's disease and levodopa-induced dyskinesia.Patients with idiopathic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::87d8f8277e4711a4fd7b611116e0b789
https://pub.dzne.de/record/138662
https://pub.dzne.de/record/138662